Maddalena Opioid Switching Score in patients with cancer pain

Pain. 2023 Jan 1;164(1):91-97. doi: 10.1097/j.pain.0000000000002669. Epub 2022 May 2.

Abstract

Evaluation of opioid switching (OS) for cancer pain has not been properly assessed. The aim of this study was to assess an integrated score (Maddalena Opioid Switching Score) as a simple and repeatable tool to evaluate the outcomes of OS, facilitating the interpretation and comparison of studies, and information exchange among researchers. The integrated score took into account pain intensity, intensity of opioid-related symptoms, and cognitive function by using an author's formula. Physical and psychological symptoms were evaluated by the Edmonton Symptom Assessment Scale and Patient Global Impression (PGI) by the minimal clinically important difference. One hundred six patients were analyzed. Ninety-five patients were switched successfully, and 11 patients underwent a further OS and/or an alternative procedure. The Maddalena Opioid Switching Score significantly decreased after OS and was highly correlated to PGI of improvement ( P < 0.0005). In patients with unsuccessful OS, no significant changes in the Maddalena Opioid Switching Score and PGI were observed. A significant reduction in Edmonton Symptom Assessment Scale items intensity was observed after OS. The Maddalena Opioid Switching Score resulted to be a sensitive instrument for measuring the clinical improvement produced by OS.

MeSH terms

  • Analgesics, Opioid / therapeutic use
  • Cancer Pain* / drug therapy
  • Cognition
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • Pain / drug therapy
  • Pain / etiology

Substances

  • Analgesics, Opioid